Trials / Recruiting
RecruitingNCT03869619
REal World Data in LYmphoma and Survival in Adults
REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,000 (estimated)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to * Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… * Document treatment effectiveness in real life and observance * Address socio-economical questions
Conditions
- Diffuse Large B Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- T-cell Lymphoma (T-NHL)
- Hodgkin's Lymphoma (HL)
- Burkitt Lymphoma (BL))
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Real-life epidemiological platform of lymphoma in France | The REALYSA database will be described with the following characteristics: * Number of patients included per month in total and according to subtype of lymphoma * Number of patients in each region in total and according to subtype of lymphoma |
Timeline
- Start date
- 2018-11-14
- Primary completion
- 2027-11-14
- Completion
- 2027-11-14
- First posted
- 2019-03-11
- Last updated
- 2021-06-28
Locations
37 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03869619. Inclusion in this directory is not an endorsement.